Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Martek, Capsugel settle, strike DHA deal

This article was originally published in The Tan Sheet

Executive Summary

After resolving a patent dispute, Capsugel agrees to purchase algae-derived DHA exclusively from Martek Biosciences. Columbia, Md.-based Martek, which filed an action for infringement against Capsugel France in November 2008, said Sept. 10 it will collaborate with the Pfizer subsidiary to add DHA to Capsugel's Licaps liquid-filled hard capsules. Martek said the patent settlement with Capsugel is not related to a separate dispute with Lonza dealing with certain patents on the life'sDHA production process (1"The Tan Sheet" Sept. 7, 2009, In Brief). After a federal appeals court ruled against Lonza in support of Martek's patents, Martek CEO Steve Dubin said Sept. 8 the firm continues to "vigorously defend its patent portfolio," which includes more than 700 granted and pending patents worldwide

You may also be interested in...



Martek looks beyond infant formulas

The maker of life'sDHA nutritional additive plans to overcome a drop in the U.S. birthrate by growing in global markets and conventional food applications. Martek Biosciences reported third-quarter revenues fell 12 percent to $77.8 million mainly due to inventory destocking, which the Columbia, Md., firm predicted (1"The Tan Sheet" June 8, 2009, In Brief). Martek's infant formula sales fell 15.4 percent, to $63.3 million, in the May-July period, although its pregnancy and nursing, nutritional supplements and animal feeds businesses shot up 58 percent to $7.9 million. Third-quarter net income dipped 4.3 percent to $8.9 million, Martek reported Sept. 2. ... DHA patents prevail: A ruling by the U.S. Court of Appeals for the Federal Circuit supports certain Martek patents on the process of extracting lipids from fermented microorganisms to produce DHA. Martek previously asserted that Swiss ingredients manufacturer Lonza infringed its patents, which Lonza said were invalid. In a Sept. 3 2decision, the court remands the case

Device Week, 24 January 2020 – Trends In Breakthrough Medical Devices

On this week’s podcast, senior reporter Elizabeth Orr highlights the most exciting medical device technology coming down the pike as part of the US FDA’s Breakthrough Devices Program.

Finance Watch: 2019 Ended With Near-Record VC Financings, But Some Slowing Expected In 2020

Private Company Edition: VC deals fell short of the record-breaking level seen in 2018 and financings may slow a bit more in 2020. Also, UPMC and Frazier close new VC funds, and Emendo raises $61m for gene-editing platform.

Topics

UsernamePublicRestriction

Register

PS103320

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel